News UK follows through on doubling of statutory scheme rate UK pharma firms have reacted angrily to the news that the government has doubled the statutory scheme rebate on the sales of newer drugs to the NHS.
News Makary, Prasad set out their vision for the FDA Top FDA officials have spelled out their strategic priorities in the coming years, including the use of AI to "increase efficiency."
News Beyfortus now has a direct rival after FDA OK for Enflonsia MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.
News Dismay as RFK Jr ousts CDC vaccine advisors RFK Jr has removed all 17 members of the CDC's vaccine advisory committee in a move that some fear could lead to restrictions on immunisation access.
News George gets FDA nod for first blood pressure triple therapy George Medicines' Widaplik can address key challenges in current hypertension treatment, according to the UK drugmaker's CEO.
News Sanofi starts shipping RSV drug early as rival nears market As an FDA decision nears from a rival MSD drug, Sanofi is speeding up the rollout of RSV antibody Beyfortus to get ahead of this year's season.
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.